V-Bio Ventures

V-Bio Ventures is an independent venture capital firm based in Ghent, Belgium, founded in 2015. The firm specializes in building and financing innovative life science companies, focusing on start-up and early-stage ventures with significant growth potential. V-Bio Ventures primarily invests in the therapeutics, diagnostic therapies, and sustainable agriculture sectors across Europe. The firm is dedicated to supporting technologies that aim to deliver transformative improvements in the biotech, pharmaceutical, and agricultural industries.

Willem Broekaert

Managing Partner

Capoen, Ward

Partner

Aurelie Nowack

Principal

Katja Rosenkranz

Partner

Christina Takke

Managing Partner

26 past transactions

Dualyx

Series A in 2023
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Precirix

Series B in 2022
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Corteria Pharmaceuticals

Seed Round in 2021
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Coave Therapeutics

Series B in 2021
Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Muna Therapeutics

Series A in 2021
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Protealis

Series A in 2021
Protealis creates improved seeds and seed technologies for legume crops in order to improve their adaptability to the European environment. The objective of the company is to be Europe's best germplasm provider for sustainable plant proteins.

AgomAb Therapeutics

Series B in 2021
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.

Oxular

Venture Round in 2021
Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.

Aphea.Bio

Series B in 2020
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Animab

Seed Round in 2020
Animab is a biotechnology company specializing in proprietary technology that supports livestock health. Animab combines cutting-edge research, animal science, and biotechnology to create products that improve animal health, reduce costs, and are more sustainable. Animab provides a safe and long-term solution for protecting piglets' intestinal health during the critical post-weaning stage. The antibodies in Animab are designed to mimic secretory IgA, a type of natural antibody that is passed through colostrum and milk to protect nursing animals.

Syndesi Therapeutics

Series A in 2020
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Biodol Therapeutics

Series A in 2020
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

ExeVir Bio

Series A in 2020
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access. ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.

Orionis Biosciences

Series B in 2020
Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

RootWave

Series A in 2020
RootWave is an electronics company that develops tools that kill weeds it enables farmers to control weeds on their farm. Its technology is an alternative substitute for herbicides and other weed control chemicals. The company was founded in 2012 and headquartered in Warwickshire, United Kingdom.

Augustine Therapeutics

Seed Round in 2019
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair.

Confo Therapeutics

Series A in 2019
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

AgomAb Therapeutics

Series A in 2019
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.

Precirix

Series A in 2018
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Coave Therapeutics

Series B in 2018
Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Syndesi Therapeutics

Series A in 2018
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Aphea.Bio

Series A in 2017
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

OCTIMET Oncology

Series A in 2017
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.

Oxular

Series A in 2016
Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.

Orionis Biosciences

Series A in 2016
Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

Confo Therapeutics

Venture Round in 2016
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.